Biomx Inc SEC Filings

BiomX (PHGE) reported Q3 2025 results marked by ongoing R&D progress alongside tight liquidity. The company posted a net loss of $9.166M and an operating loss of $8.536M. R&D expenses, net, were $6.122M (down 16% year over year), and G&A expenses were $2.414M (down 25%).

Cash resources remain limited. Cash, cash equivalents and restricted cash were $8.069M at September 30, 2025. For the nine months, cash used in operating activities totaled $22.004M, partly offset by $11.938M of financing inflows, including February 2025 capital actions and modest ATM sales. Management states current funds are sufficient into Q1 2026 and notes substantial doubt about the ability to continue as a going concern.

On the pipeline, the Phase 2b CF study of BX004 continues in Europe, while the FDA placed a clinical hold in August 2025 related to the third‑party nebulizer device; no issues were raised regarding BX004 itself. BiomX believes it has addressed FDA device queries and expects topline results in Q1 2026. The company also reported positive Phase 2 results in DFO (BX211) and plans to advance BX011 in DFI subject to resources. Shares outstanding were 29,006,165 as of November 11, 2025.

BiomX Inc. (PHGE) filed an 8-K stating it furnished a press release announcing financial results for the third quarter ended September 30, 2025. The release was provided under Item 2.02 and attached as Exhibit 99.1. This is a standard disclosure to make the company’s quarterly results announcement part of the public record.

BiomX Inc. (PHGE) reported voting results from its 2025 Annual Meeting. Stockholders approved authorizing the Board to amend the certificate of incorporation to effect a reverse stock split of the outstanding Common Stock at any ratio between at least 1-for-5 and less than 1-for-20, with 13,641,280 votes for, 383,712 against, and 71,143 abstaining.

Three Class II directors—Susan Blum, Dr. Jesse Goodman, and Gregory Merril—were elected to serve until the 2028 annual meeting. Stockholders also ratified Kesselman & Kesselman, a member firm of PwC International Limited, as the independent registered public accounting firm for fiscal 2025 (14,050,210 for; 25,633 against; 20,294 abstaining). A proposal to adjourn the meeting was not called.

BiomX Inc. (PHGE) updated its Phase 2b BX004 program for cystic fibrosis. The FDA sent additional, narrow questions focused solely on the third‑party nebulizer used to deliver BX004, with no concerns raised about the drug itself. BiomX believes it has fully addressed these device-related queries.

Enrollment and dosing in the European portion of the study are proceeding ahead of plan, and topline results remain on track for the first quarter of 2026. The FDA also provided new written feedback recognizing the unmet need in chronic Pseudomonas aeruginosa infection and outlined potential development pathways, including refined inclusion criteria and approaches to enrich patient populations for a potential Phase 3 program.

BiomX plans to incorporate the FDA’s recommendations, as appropriate and subject to future study data, regulatory alignment, and resources, and anticipates an End-of-Phase 2 meeting after completion and review of the Phase 2b results.

BiomX Inc. will hold its 2025 annual meeting virtually on October 16, 2025 at 8:00 a.m. Eastern Time for holders of record as of August 22, 2025. Key proposals include authorization for the Board to implement a reverse stock split of common stock at a ratio between 1-for-5 and less than 1-for-20 to be effected by October 16, 2026, ratification of Kesselman & Kesselman (a PwC member firm) as independent auditors for fiscal 2025, and approval to adjourn the meeting if necessary to continue soliciting votes. The proxy describes voting methods (written notice, later-dated proxy online/telephone, or electronic voting during the meeting), lists Board nominees and committee structure, summarizes an insider trading policy with specific prohibited transactions, and discloses certain audit fees and significant stockholders including two holders each with 9.9% stakes and Nantahala Capital Management at 9.9%.

BiomX Inc. (PHGE) is soliciting proxies for its virtual Annual Meeting to be held at 8:00 a.m. Eastern Time on Thursday, October 16, 2025, accessible at www.virtualshareholdermeeting.com/PHGE2025. The Board fixed August 22, 2025 as the record date for shareholders entitled to vote. Key proposals described in the proxy include authorizing the Board to implement a reverse stock split of common stock at any ratio between 1-for-5 and less than 1-for-20 to be effected at the Board's discretion before October 16, 2026, ratifying Kesselman & Kesselman (a PwC member firm) as the independent registered public accounting firm for fiscal 2025, and approving adjournment/postponement to continue soliciting votes. The notice explains admission and proxy voting procedures and references the proxy statement for full details.

BiomX Inc. (PHGE) amended its Form S-3 prospectus to update the amount it may sell under an existing at-the-market (ATM) agreement with H.C. Wainwright. The company currently may offer and sell up to $1,765,939 of common stock under General Instruction I.B.6 of Form S-3, excluding approximately $20,734 already sold under the prior prospectus. The aggregate market value of shares held by non-affiliates used in the calculation is $15,441,621, based on 23,756,340 non-affiliate shares at $0.65 per share. BiomX has sold $3,381,268 under the same instruction during the prior 12-month period. Common stock trades on the NYSE American under PHGE; the last reported sale price was $0.56.

BiomX Inc. (PHGE) reported continuing clinical progress alongside notable financing activity but disclosed material financing pressure. The company held $15.19 million in total cash and restricted cash at June 30, 2025 (amounts presented in USD in thousands) and recorded a net loss of $13.7 million for the six months ended June 30, 2025. Operating cash used was $14.82 million for the six-month period, and accumulated deficit totaled $194.39 million, raising substantial doubt about the company’s ability to continue as a going concern.

On the clinical front, BiomX reported positive Phase 2 results for BX211 in diabetic foot osteomyelitis with a statistically significant percent area reduction of ulcers (p = 0.046 at week 12) and other favorable secondary trends. BX004 (CF) advanced into a randomized Phase 2b with first patient dosed July 14, 2025, and holds FDA Fast Track and Orphan Drug designations. The company completed equity and warrant financings in 2024–2025 and recorded gross proceeds from the February 2025 SPA of $5,527 and related financings and warrant exercises that provided cash in the period, but management states current funds are not sufficient to fund operations for at least one year without additional financing.